A new animal free alternative to study atherosclerosis

Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.

Analysis of breast and prostate cancer with artificial intelligence for improved care

The cancer grade, provided by pathologists, is the most important predictor of patient outcome, but suffers from inter- and intra-pathologist variability, reducing its usefulness for individual patients. An expert-level AI system will be provided to support pathologist and help reduce this variability and make their diagnostic practice more accurate and efficient.

Better Sleep

The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.

Food supplements to boost brain function – mind your blood vessels

This project aims to unravel mechanisms underlying beneficial effects of a novel food supplement on cognitive performance. This may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on adults with an emerging pre-mild cognitive impairment condition who will benefit most from evidence-based intervention and prevention strategies.